David Scott Moore Buys 21,700 Shares of Corvus Pharmaceuticals (NASDAQ:CRVS) Stock

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Director David Scott Moore acquired 21,700 shares of the company’s stock in a transaction on Thursday, June 11th. The stock was acquired at an average price of $11.53 per share, for a total transaction of $250,201.00. Following the completion of the purchase, the director owned 21,700 shares of the company’s stock, valued at $250,201. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Corvus Pharmaceuticals Stock Performance

NASDAQ CRVS opened at $11.74 on Wednesday. The firm has a market cap of $987.22 million, a PE ratio of -22.58 and a beta of 0.84. Corvus Pharmaceuticals, Inc. has a one year low of $3.55 and a one year high of $26.95. The firm’s fifty day moving average is $13.89 and its two-hundred day moving average is $13.73.

Corvus Pharmaceuticals (NASDAQ:CRVS) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). Research analysts predict that Corvus Pharmaceuticals, Inc. will post -0.7 earnings per share for the current year.

Wall Street Analysts Forecast Growth

CRVS has been the topic of a number of recent analyst reports. Weiss Ratings upgraded shares of Corvus Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, April 29th. Wall Street Zen downgraded shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Oppenheimer reissued an “outperform” rating and set a $33.00 price objective (up from $32.00) on shares of Corvus Pharmaceuticals in a report on Friday, March 13th. The Goldman Sachs Group began coverage on shares of Corvus Pharmaceuticals in a report on Friday, April 17th. They set a “buy” rating and a $40.00 price objective on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Corvus Pharmaceuticals in a report on Friday, March 13th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $33.33.

Institutional Trading of Corvus Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in CRVS. Geode Capital Management LLC lifted its position in shares of Corvus Pharmaceuticals by 130.7% in the second quarter. Geode Capital Management LLC now owns 1,361,740 shares of the company’s stock valued at $5,448,000 after acquiring an additional 771,454 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Corvus Pharmaceuticals by 541.9% in the second quarter. JPMorgan Chase & Co. now owns 30,420 shares of the company’s stock valued at $122,000 after acquiring an additional 25,681 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Corvus Pharmaceuticals by 9,501.8% in the second quarter. Rhumbline Advisers now owns 75,950 shares of the company’s stock valued at $304,000 after acquiring an additional 75,159 shares in the last quarter. Hsbc Holdings PLC purchased a new stake in shares of Corvus Pharmaceuticals in the second quarter valued at $332,000. Finally, New York State Common Retirement Fund purchased a new position in shares of Corvus Pharmaceuticals during the second quarter valued at approximately $95,000. 46.64% of the stock is currently owned by hedge funds and other institutional investors.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.